Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Paricalcitol
Drug ID BADD_D01676
Description Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
Indications and Usage For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
Marketing Status Prescription; Discontinued
ATC Code H05BX02
DrugBank ID DB00910
KEGG ID D00930
MeSH ID C084656
PubChem ID 5281104
TTD Drug ID D0N1TP
NDC Product Code 25000-012; 70121-1036; 65862-938; 68382-331; 68513-1054; 25000-014; 66499-0019; 0409-1008; 63629-2452; 69452-145; 17478-033; 25000-017; 10888-8103; 0143-9625; 67457-692; 70121-1035; 49483-687; 43598-563; 55150-213; 48943-0033; 58032-1001; 55111-663; 70121-1034; 69452-146; 65862-937; 55150-214; 68382-330; 0143-9624; 11014-0053; 43598-564; 43598-565; 43598-562; 0074-9036; 55111-665; 63629-2453; 0074-1658; 55150-212; 10888-8102; 55150-215; 65162-822; 58272-192; 49483-689; 0409-1007; 65162-824; 49483-688; 65162-823; 55111-664; 69452-147; 11014-0048; 16729-310; 0074-9037; 16729-311; 70121-1033; 67457-380; 65862-936; 10888-8104; 0143-9596; 0074-4637; 14474-021
Synonyms paricalcitol | 19-nor-1alpha,25-dihydroxyvitamin D2 | 19-nor-1,25-(OH)2D2 | Zemplar | paricalcitol-d6
Chemical Information
Molecular Formula C27H44O3
CAS Registry Number 131918-61-1
SMILES CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Adverse drug reactionAlkaline phosphatase, placental typeP05187Not Available11576883; 9697664; 9808143
Adverse drug reactionParathyroid hormone/parathyroid hormone-related peptide receptorQ03431T6771011576883; 9697664; 9808143
Electrolyte imbalanceGastrin/cholecystokinin type B receptorP32239T0584912529809; 12073167; 9160584; 7619662
Iron and trace metal metabolism disordersParathyroid hormone/parathyroid hormone-related peptide receptorQ03431T6771011576883; 9697664; 9808143
Iron and trace metal metabolism disordersAlkaline phosphatase, placental typeP05187Not Available11576883; 9697664; 9808143
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Haemorrhagic stroke24.07.04.014; 17.08.01.0110.030498%Not Available
Headache17.14.01.001--
Heart rate irregular13.14.04.003--Not Available
Hepatic cirrhosis09.01.04.001--Not Available
Hepatic failure09.01.03.002--
Hip fracture12.04.01.001; 15.08.03.001--
Hirsutism23.02.04.001; 05.05.01.005--
Hypercalcaemia05.04.01.002; 14.04.01.0030.044964%
Hypercholesterolaemia14.08.01.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.001--
Hyperparathyroidism05.04.01.001--
Hyperphosphataemia14.04.03.0070.002346%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypertensive crisis24.08.01.0010.009384%Not Available
Hypertensive heart disease24.08.05.002; 02.01.04.0010.003519%Not Available
Hypervolaemia14.05.06.003--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypocalcaemia14.04.01.004--
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypoparathyroidism14.04.01.007; 12.02.15.001; 05.04.02.001--
Hypotension24.06.03.002--
Hypotonia17.05.02.002; 15.05.04.008--Not Available
Hypovolaemia14.05.05.0020.002346%Not Available
Hypovolaemic shock24.06.02.0170.010557%Not Available
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.0020.154834%Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Injection site extravasation12.07.03.002; 08.02.03.002--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 12 Pages